Affordable Access

deepdyve-link
Publisher Website

Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence

Authors
  • Asensio, Enrique1
  • Acunzo, Rafael2
  • Uribe, William3
  • Saad, Eduardo B.4
  • Sáenz, Luis C.5
  • 1 Division of Internal Medicine, Hospital H, Querétaro, Mexico
  • 2 Hospital Ramos Mejía,
  • 3 CES Cardiología, Medellín, Colombia
  • 4 Hospital Pró-Cardíaco,
  • 5 International Center of Arrhythmias, Fundación CardioInfantilI-Instituto de Cardiología,
Type
Published Article
Journal
Journal of Interventional Cardiac Electrophysiology
Publisher
Springer-Verlag
Publication Date
May 16, 2020
Pages
1–6
Identifiers
DOI: 10.1007/s10840-020-00765-3
PMID: 32418181
PMCID: PMC7229438
Source
PubMed Central
Keywords
License
Unknown

Abstract

COVID-19 infection has shown rapid growth worldwide, and different therapies have been proposed for treatment, in particular, the combination of immune response modulating drugs such as chloroquine and hydroxychloroquine (antimalarials) alone or in combination with azithromycin. Although the clinical evidence supporting their use is scarce, the off label use of these drugs has spread very quickly in face of the progression of the epidemic and the high mortality rate in susceptible populations. However, these medications can pathologically prolong the QT interval and lead to malignant ventricular arrhythmias such that organized guidance on QT evaluation and management strategies are important to reduce morbidity associated with the potential large-scale use.

Report this publication

Statistics

Seen <100 times